Comment on Shuhaibar et al.: Favourable effect of immunomodulator therapy on bone mineral density in multiple sclerosis.
Kampman
M T
MT
Steffensen
L H
LH
D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000328:Adult; D015519:Bone Density / Q000187:drug effects*; D016022:Case-Control Studies; D005260:Female; D000068717:Glatiramer Acetate; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D000068556:Interferon beta-1a; D000068576:Interferon beta-1b; D016899:Interferon-beta / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000188:drug therapy*; D010455:Peptides / Q000627:therapeutic use
D000276:Adjuvants, Immunologic; D007155:Immunologic Factors; D007166:Immunosuppressive Agents; D010455:Peptides; D000068576:Interferon beta-1b; D000068717:Glatiramer Acetate; D016899:Interferon-beta; D000068556:Interferon beta-1a